Predictive Oncology Inc
POAI7.210USD
-1.030-12.50%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
4.61MMarket Cap
LossP/E TTM
More Details of Predictive Oncology Inc Company
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
Predictive Oncology Inc Info
Ticker SymbolPOAI
Company namePredictive Oncology Inc
IPO dateDec 18, 2009
CEOMr. Raymond F. Vennare
Number of employees23
Security typeOrdinary Share
Fiscal year-endDec 18
Address91 43Rd Street
CityPITTSBURGH
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code15201
Phone14124321500
Websitehttps://predictive-oncology.com/
Ticker SymbolPOAI
IPO dateDec 18, 2009
CEOMr. Raymond F. Vennare
Company Executives of Predictive Oncology Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.81K
--
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
6.47K
--
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
5.45K
--
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
4.92K
--
Mr. Thomas McLaughlin
Mr. Thomas McLaughlin
Chief Investment Officer
Chief Investment Officer
--
--
Ms. Sara Turken
Ms. Sara Turken
General Counsel
General Counsel
--
--
Mr. Shawn P. Matthews
Mr. Shawn P. Matthews
Director
Director
--
--
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.81K
--
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
6.47K
--
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
5.45K
--
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
4.92K
--
Mr. Thomas McLaughlin
Mr. Thomas McLaughlin
Chief Investment Officer
Chief Investment Officer
--
--
Ms. Sara Turken
Ms. Sara Turken
General Counsel
General Counsel
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Oct 30
Updated: Thu, Oct 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Luo (Weiyu)
12.28%
SLN Capital Ltd
7.37%
Vennare (Raymond F)
0.25%
Blacher (Joshua)
0.18%
Nuzum (Charles Lee Sr)
0.18%
Other
79.73%
Shareholders
Shareholders
Proportion
Luo (Weiyu)
12.28%
SLN Capital Ltd
7.37%
Vennare (Raymond F)
0.25%
Blacher (Joshua)
0.18%
Nuzum (Charles Lee Sr)
0.18%
Other
79.73%
Shareholder Types
Shareholders
Proportion
Individual Investor
13.66%
Corporation
7.37%
Investment Advisor/Hedge Fund
0.15%
Investment Advisor
0.14%
Research Firm
0.03%
Endowment Fund
0.02%
Other
78.63%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
36
12.13K
0.35%
-21.27K
2025Q2
44
299.51K
2.93%
-288.64K
2025Q1
50
299.35K
3.35%
-293.31K
2024Q4
56
353.94K
4.97%
-213.96K
2024Q3
54
322.08K
5.97%
-246.26K
2024Q2
57
408.73K
8.00%
-114.07K
2024Q1
66
484.20K
11.91%
-86.59K
2023Q4
66
502.45K
12.36%
-67.11K
2023Q3
69
499.46K
12.41%
-50.95K
2023Q2
67
353.15K
8.84%
-144.84K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Vennare (Raymond F)
8.81K
1.16%
+8.33K
+1753.89%
Sep 09, 2025
Blacher (Joshua)
6.47K
0.85%
+6.47K
--
Sep 09, 2025
Nuzum (Charles Lee Sr)
6.31K
0.83%
+4.31K
+216.25%
Sep 09, 2025
St Clair (Gregory Sr)
5.72K
0.75%
+4.31K
+305.17%
Sep 09, 2025
Chung-Welch (Nancy)
5.60K
0.73%
+4.31K
+334.78%
Sep 09, 2025
Handley (Daniel E)
5.45K
0.71%
+4.31K
+379.91%
Sep 09, 2025
Hawryluk (Matthew)
4.95K
0.65%
+4.31K
+681.20%
Sep 09, 2025
Rao (Veena)
4.92K
0.65%
+4.31K
+709.21%
Sep 09, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Date
Type
Ratio
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
